Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives throughout more than 100 countries. Valeant’s primary focus is in the areas of dermatology and eye health. Valeant has an established portfolio of durable products and our strategy is to focus the business on core geographies and therapeutic areas that offer high-growth opportunities. Another critical element of our strategy is business development. We have completed numerous transactions over the past few years, including the acquisition of international eye health organization Bausch + Lomb in 2013, to expand our portfolio and our geographic footprint. We will continue to pursue value-added business development opportunities as they arise. Valeant’s strategic markets are primarily in the United States, Canada, Europe, the Middle East, Latin America, Asia Pacific and Africa.
Company Growth (employees)
Aliso Viejo, US
Size (employees)
21,500 (est)
Valeant Pharmaceuticals International was founded in 1960 and is headquartered in Aliso Viejo, US

Key People/Management at Valeant Pharmaceuticals International

Joe Papa

Joe Papa


Valeant Pharmaceuticals International Office Locations

Valeant Pharmaceuticals International has an office in Aliso Viejo
Show all (1)

Valeant Pharmaceuticals International Financials and Metrics

Valeant Pharmaceuticals International Financials

Valeant Pharmaceuticals International's revenue was reported to be $9.7 b in FY, 2016

Revenue (Q2, 2017)

2.2 b

Gross profit (Q2, 2017)

1.6 b

Gross profit margin (Q2, 2017), %


Net income (Q2, 2017)

(37 m)

EBIT (Q2, 2017)

175 m

Market capitalization (22-Dec-2017)

7.6 b

Cash (30-Jun-2017)

1.2 b
Valeant Pharmaceuticals International's current market capitalization is $7.6 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


5.8 b8.3 b10.4 b9.7 b

Revenue growth, %


Cost of goods sold

1.8 b

Gross profit

3.9 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


1.5 b1.9 b2.8 b2.1 b2.2 b

Cost of goods sold

560.9 m504.1 m634.6 m584 m635 m

Gross profit

980.9 m1.4 b2.2 b1.5 b1.6 b

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


600.3 m322.6 m597.3 m542 m

Accounts Receivable

1.8 b2.1 b2.7 b2.5 b


205 m641.9 m966.4 m1.1 b

Current Assets

3.9 b4.2 b5.5 b5.1 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


596.3 m576.3 m531.2 m808.8 m1.9 b958 m1.4 b1.3 b852.4 m658.5 m1.2 b1.2 b

Accounts Receivable

1.6 b1.7 b1.8 b1.9 b2.1 b2.4 b2.7 b2.7 b2.7 b2.7 b2.1 b2.1 b


1.1 b953.4 m942.5 m932.7 m998.9 m1.2 b1.2 b1.3 b1.3 b1.3 b1.1 b1.1 b

Current Assets

3.8 b4 b5.2 b4.4 b16.2 b6.3 b7 b6.2 b5.8 b5.7 b5.3 b6 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(863.7 m)912.2 m(287.8 m)(2.4 b)

Accounts Receivable

(260 m)


(120 m)(170 m)(280 m)(164 m)

Cash From Operating Activities

1 b2.3 b2.2 b2.1 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(972 m)(20.3 m)122 m276.4 m74.5 m(51.6 m)51.7 m(372.9 m)(676.9 m)(1.9 b)629 m592 m

Depreciation and Amortization

635 m

Accounts Receivable

53 m


(46.2 m)(69.2 m)(12.1 m)(41.5 m)(38.5 m)(48.3 m)(45.6 m)(85.9 m)(145.1 m)(166.3 m)(38 m)
Y, 2017

Financial Leverage

10.4 x
Show all financial metrics

Valeant Pharmaceuticals International Market Value History

Valeant Pharmaceuticals International's Web-traffic and Trends

Valeant Pharmaceuticals International Online and Social Media Presence

Valeant Pharmaceuticals International Company Life and Culture

You may also be interested in